{
    "clinical_study": {
        "@rank": "57003", 
        "arm_group": {
            "arm_group_label": "Trivalent Influenza Vaccine", 
            "arm_group_type": "Experimental", 
            "description": "The study vaccine is a sterile, thiomersal-free suspension containing 45 mcg total haemagglutinin antigen per 0.5 mL dose (15 mcg each of the three recommended influenza strains for the Northern Hemisphere 2013/2014 influenza season).  The vaccine will be administered by intramuscular or deep subcutaneous injection."
        }, 
        "brief_summary": {
            "textblock": "This is a study to assess the immune (antibody) response and safety of a bioCSL split\n      virion, inactivated influenza vaccine containing the 2013/2014 formulation of Enzira\u00ae\n      vaccine in healthy adult volunteers aged between 18 and 60 years."
        }, 
        "brief_title": "A Study to Assess the Immunogenicity and Safety of a Trivalent Influenza Vaccine Containing the 2013/2014 Formulation of Enzira\u00ae Vaccine in Healthy Volunteers", 
        "clinical_results": {
            "baseline": {
                "group_list": {
                    "group": {
                        "@group_id": "B1", 
                        "description": "Healthy volunteers aged between 18 and 60 years received a single 0.5 mL dose of Trivalent Influenza Vaccine by intramuscular or subcutaneous injection.", 
                        "title": "Trivalent Influenza Vaccine"
                    }
                }, 
                "measure_list": {
                    "measure": [
                        {
                            "category_list": {
                                "category": {
                                    "measurement_list": {
                                        "measurement": {
                                            "@group_id": "B1", 
                                            "@value": "120"
                                        }
                                    }
                                }
                            }, 
                            "param": "Number", 
                            "title": "Number of Participants", 
                            "units": "participants"
                        }, 
                        {
                            "category_list": {
                                "category": {
                                    "measurement_list": {
                                        "measurement": {
                                            "@group_id": "B1", 
                                            "@spread": "10.12", 
                                            "@value": "31.8"
                                        }
                                    }
                                }
                            }, 
                            "dispersion": "Standard Deviation", 
                            "param": "Mean", 
                            "title": "Age, Customized", 
                            "units": "years"
                        }, 
                        {
                            "category_list": {
                                "category": [
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "63"
                                            }
                                        }, 
                                        "sub_title": "Female"
                                    }, 
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "57"
                                            }
                                        }, 
                                        "sub_title": "Male"
                                    }
                                ]
                            }, 
                            "param": "Number", 
                            "title": "Gender", 
                            "units": "participants"
                        }
                    ]
                }
            }, 
            "certain_agreements": {
                "pi_employee": "Principal Investigators are NOT employed by the organization sponsoring the study.", 
                "restrictive_agreement": "CSL agreements and restrictions on publishing may vary with individual investigators; however, CSL will not prohibit any investigator from publishing. CSL supports the publication of results from all centers of a multi-center trial and generally requires that reports based on single-site data not precede the primary publication of the entire clinical trial."
            }, 
            "outcome_list": {
                "outcome": [
                    {
                        "description": "As per the criteria specified in the CPMP/BWP/214/96 Note for Guidance on Harmonisation of Requirements for Influenza Vaccines. For haemagglutination inhibition (HI), seroconversion (H1N1, H3N2, and B influenza virus strains) is defined as achieving a post-vaccination titre of \u2265 40 for those participants with a pre-vaccination HI titre of < 10.  A significant increase (H1N1, H3N2, and B influenza virus strains) is defined as a four-fold or greater increase in HI titre for those participants with a pre-vaccination HI titre of \u2265 10.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Healthy volunteers aged between 18 and 60 years received a single 0.5 mL dose of Trivalent Influenza Vaccine by intramuscular or subcutaneous injection.", 
                                "title": "Trivalent Influenza Vaccine"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "119"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@lower_limit": "70.6", 
                                                        "@upper_limit": "85.9", 
                                                        "@value": "79"
                                                    }
                                                }, 
                                                "sub_title": "H1N1 strain"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@lower_limit": "70.6", 
                                                        "@upper_limit": "85.9", 
                                                        "@value": "79"
                                                    }
                                                }, 
                                                "sub_title": "H3N2 strain"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@lower_limit": "55.4", 
                                                        "@upper_limit": "73.2", 
                                                        "@value": "64.7"
                                                    }
                                                }, 
                                                "sub_title": "B strain"
                                            }
                                        ]
                                    }, 
                                    "description": "As per the criteria specified in the CPMP/BWP/214/96 Note for Guidance on Harmonisation of Requirements for Influenza Vaccines. For haemagglutination inhibition (HI), seroconversion (H1N1, H3N2, and B influenza virus strains) is defined as achieving a post-vaccination titre of \u2265 40 for those participants with a pre-vaccination HI titre of < 10.  A significant increase (H1N1, H3N2, and B influenza virus strains) is defined as a four-fold or greater increase in HI titre for those participants with a pre-vaccination HI titre of \u2265 10.", 
                                    "dispersion": "95% Confidence Interval", 
                                    "param": "Number", 
                                    "title": "The Percentage of Evaluable Participants Achieving Seroconversion or Significant Increase in Antibody Titre.", 
                                    "units": "percentage of participants"
                                }
                            ]
                        }, 
                        "population": "The Evaluable Population includes all participants who were vaccinated with Trivalent Influenza Vaccine, provided both pre- and post-vaccination antibody titre results, did not use a prohibited medication as per the protocol, and were not excluded from the analysis according to the elimination criteria.", 
                        "safety_issue": "No", 
                        "time_frame": "Approximately 21 days after vaccination", 
                        "title": "The Percentage of Evaluable Participants Achieving Seroconversion or Significant Increase in Antibody Titre.", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "GMFI (H1N1, H3N2, and B influenza virus strains) is defined as the geometric mean of the fold increases of post-vaccination antibody titre over the pre-vaccination antibody titre.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Healthy volunteers aged between 18 and 60 years received a single 0.5 mL dose of Trivalent Influenza Vaccine by intramuscular or subcutaneous injection.", 
                                "title": "Trivalent Influenza Vaccine"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "119"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "4.27", 
                                                        "@value": "15.01"
                                                    }
                                                }, 
                                                "sub_title": "H1N1 strain"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "4.494", 
                                                        "@value": "13.18"
                                                    }
                                                }, 
                                                "sub_title": "H3N2 strain"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "3.461", 
                                                        "@value": "5.86"
                                                    }
                                                }, 
                                                "sub_title": "B strain"
                                            }
                                        ]
                                    }, 
                                    "description": "GMFI (H1N1, H3N2, and B influenza virus strains) is defined as the geometric mean of the fold increases of post-vaccination antibody titre over the pre-vaccination antibody titre.", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Geometric Mean", 
                                    "title": "The Geometric Mean Fold Increase (GMFI) in Antibody Titre After Vaccination.", 
                                    "units": "fold increase"
                                }
                            ]
                        }, 
                        "population": "The Evaluable Population includes all participants who were vaccinated with Trivalent Influenza Vaccine, provided both pre- and post-vaccination antibody titre results, did not use a prohibited medication as per the protocol, and were not excluded from the analysis according to the elimination criteria.", 
                        "safety_issue": "No", 
                        "time_frame": "Approximately 21 days after vaccination", 
                        "title": "The Geometric Mean Fold Increase (GMFI) in Antibody Titre After Vaccination.", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "For the H1N1, H3N2, and B influenza virus strains. Note: No SRH data were collected.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Healthy volunteers aged between 18 and 60 years received a single 0.5 mL dose of Trivalent Influenza Vaccine by intramuscular or subcutaneous injection.", 
                                "title": "Trivalent Influenza Vaccine"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "119"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@lower_limit": "92.8", 
                                                        "@upper_limit": "99.5", 
                                                        "@value": "97.5"
                                                    }
                                                }, 
                                                "sub_title": "H1N1 strain"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@lower_limit": "95.4", 
                                                        "@upper_limit": "100.0", 
                                                        "@value": "99.2"
                                                    }
                                                }, 
                                                "sub_title": "H3N2 strain"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@lower_limit": "89.3", 
                                                        "@upper_limit": "98.1", 
                                                        "@value": "95.0"
                                                    }
                                                }, 
                                                "sub_title": "B strain"
                                            }
                                        ]
                                    }, 
                                    "description": "For the H1N1, H3N2, and B influenza virus strains. Note: No SRH data were collected.", 
                                    "dispersion": "95% Confidence Interval", 
                                    "param": "Number", 
                                    "title": "The Percentage of Evaluable Participants Achieving a HI Titre \u2265 40 or Single Radial Haemolysis (SRH) Area \u2265 25 mm2.", 
                                    "units": "percentage of participants"
                                }
                            ]
                        }, 
                        "population": "The Evaluable Population includes all participants who were vaccinated with Trivalent Influenza Vaccine, provided both pre- and post-vaccination antibody titre results, did not use a prohibited medication as per the protocol, and were not excluded from the analysis according to the elimination criteria.", 
                        "safety_issue": "No", 
                        "time_frame": "Approximately 21 days after vaccination", 
                        "title": "The Percentage of Evaluable Participants Achieving a HI Titre \u2265 40 or Single Radial Haemolysis (SRH) Area \u2265 25 mm2.", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "The percentage of participants reporting any solicited AEs.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Healthy volunteers aged between 18 and 60 years received a single 0.5 mL dose of Trivalent Influenza Vaccine by intramuscular or subcutaneous injection.", 
                                "title": "Trivalent Influenza Vaccine"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "120"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "52.5"
                                                    }
                                                }, 
                                                "sub_title": "Any solicited local AE"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "0.8"
                                                    }
                                                }, 
                                                "sub_title": "Induration > 50 mm"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "10"
                                                    }
                                                }, 
                                                "sub_title": "Erythema"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "8.3"
                                                    }
                                                }, 
                                                "sub_title": "Ecchymosis"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "51.7"
                                                    }
                                                }, 
                                                "sub_title": "Pain"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "19.2"
                                                    }
                                                }, 
                                                "sub_title": "Any solicited systemic AE"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "0"
                                                    }
                                                }, 
                                                "sub_title": "Temperature > 38\u00b0C for \u2265 24 hours"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "10.8"
                                                    }
                                                }, 
                                                "sub_title": "Chills"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "17.5"
                                                    }
                                                }, 
                                                "sub_title": "Malaise"
                                            }
                                        ]
                                    }, 
                                    "description": "The percentage of participants reporting any solicited AEs.", 
                                    "param": "Number", 
                                    "title": "Type and Frequency of Any Solicited Adverse Events (AEs)", 
                                    "units": "percentage of participants"
                                }
                            ]
                        }, 
                        "population": "The Safety Population included all participants who received Trivalent Influenza Vaccine and provided follow-up safety data.", 
                        "safety_issue": "Yes", 
                        "time_frame": "During the 4 days after vaccination (Day 0 plus 3 days)", 
                        "title": "Type and Frequency of Any Solicited Adverse Events (AEs)", 
                        "type": "Secondary"
                    }, 
                    {
                        "description": "The percentage of participants reporting any unsolicited AEs. Unsolicited AEs included AEs other than those specifically solicited.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Healthy volunteers aged between 18 and 60 years received a single 0.5 mL dose of Trivalent Influenza Vaccine by intramuscular or subcutaneous injection.", 
                                "title": "Trivalent Influenza Vaccine"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "120"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "44.2"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "The percentage of participants reporting any unsolicited AEs. Unsolicited AEs included AEs other than those specifically solicited.", 
                                    "param": "Number", 
                                    "title": "Type and Frequency of Any Unsolicited AEs", 
                                    "units": "percentage of participants"
                                }
                            ]
                        }, 
                        "population": "The Safety Population included all participants who received Trivalent Influenza Vaccine and provided follow-up safety data.", 
                        "safety_issue": "Yes", 
                        "time_frame": "After vaccination until the end of the study; approximately 21 days.", 
                        "title": "Type and Frequency of Any Unsolicited AEs", 
                        "type": "Secondary"
                    }
                ]
            }, 
            "participant_flow": {
                "group_list": {
                    "group": {
                        "@group_id": "P1", 
                        "description": "Healthy volunteers aged between 18 and 60 years received a single 0.5 mL dose of Trivalent Influenza Vaccine by intramuscular or subcutaneous injection.", 
                        "title": "Trivalent Influenza Vaccine"
                    }
                }, 
                "period_list": {
                    "period": {
                        "drop_withdraw_reason_list": {
                            "drop_withdraw_reason": {
                                "participants_list": {
                                    "participants": {
                                        "@count": "1", 
                                        "@group_id": "P1"
                                    }
                                }, 
                                "title": "Protocol Violation"
                            }
                        }, 
                        "milestone_list": {
                            "milestone": [
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "120", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "STARTED"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": {
                                            "#text": "1 subject was withdrawn from the study due to evidence of substance abuse.", 
                                            "@count": "119", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "COMPLETED"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "1", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "NOT COMPLETED"
                                }
                            ]
                        }, 
                        "title": "Overall Study"
                    }
                }, 
                "recruitment_details": "The study was open label, non-randomized with single group assignment in healthy volunteers aged 18 to 60 years."
            }, 
            "point_of_contact": {
                "email": "csl.clinicaltrials@csl.com.au", 
                "name_or_title": "bioCSL, Head of Clinical Operations", 
                "organization": "bioCSL PTY LTD", 
                "phone": "csl.clinicaltrials@csl.com.au"
            }, 
            "reported_events": {
                "desc": "The other AEs presented include solicited and unsolicited AEs. The Safety Population included all participants who received Trivalent Influenza Vaccine and provided follow-up safety data.", 
                "group_list": {
                    "group": {
                        "@group_id": "E1", 
                        "description": "Healthy volunteers aged between 18 and 60 years received a single 0.5 mL dose of Trivalent Influenza Vaccine by intramuscular or subcutaneous injection.", 
                        "title": "Trivalent Influenza Vaccine"
                    }
                }, 
                "other_events": {
                    "category_list": {
                        "category": [
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@group_id": "E1", 
                                            "@subjects_affected": "81", 
                                            "@subjects_at_risk": "120"
                                        }, 
                                        "sub_title": "Total, other adverse events"
                                    }
                                }, 
                                "title": "Total"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@events": "13", 
                                            "@group_id": "E1", 
                                            "@subjects_affected": "13", 
                                            "@subjects_at_risk": "120"
                                        }, 
                                        "sub_title": "Chills"
                                    }
                                }, 
                                "title": "Gastrointestinal disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": [
                                        {
                                            "counts": {
                                                "@events": "64", 
                                                "@group_id": "E1", 
                                                "@subjects_affected": "62", 
                                                "@subjects_at_risk": "120"
                                            }, 
                                            "sub_title": "Injection site pain"
                                        }, 
                                        {
                                            "counts": {
                                                "@events": "21", 
                                                "@group_id": "E1", 
                                                "@subjects_affected": "21", 
                                                "@subjects_at_risk": "120"
                                            }, 
                                            "sub_title": "Malaise"
                                        }, 
                                        {
                                            "counts": {
                                                "@events": "12", 
                                                "@group_id": "E1", 
                                                "@subjects_affected": "12", 
                                                "@subjects_at_risk": "120"
                                            }, 
                                            "sub_title": "Injection site erythema"
                                        }, 
                                        {
                                            "counts": {
                                                "@events": "10", 
                                                "@group_id": "E1", 
                                                "@subjects_affected": "10", 
                                                "@subjects_at_risk": "120"
                                            }, 
                                            "sub_title": "Injection site haemorrhage"
                                        }
                                    ]
                                }, 
                                "title": "General disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "assessment": "Non-systematic Assessment", 
                                        "counts": {
                                            "@events": "41", 
                                            "@group_id": "E1", 
                                            "@subjects_affected": "32", 
                                            "@subjects_at_risk": "120"
                                        }, 
                                        "description": "Unsolicited adverse event", 
                                        "sub_title": "Headache"
                                    }
                                }, 
                                "title": "Nervous system disorders"
                            }
                        ]
                    }, 
                    "default_assessment": "Systematic Assessment", 
                    "default_vocab": "MedDRA 16", 
                    "frequency_threshold": "5"
                }, 
                "time_frame": "For solicited AEs: During the 4 days after vaccination (Day 0 plus 3 days); For unsolicited AEs and serious AEs (SAEs): After vaccination until the end of the study (approximately 21 days)."
            }
        }, 
        "completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "condition": "Influenza, Human", 
        "condition_browse": {
            "mesh_term": "Influenza, Human"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Males or females aged between 18 and 60 years at the time of vaccination.\n\n          -  Females of child-bearing potential (i.e., ovulating, pre-menopausal, not surgically\n             sterile) must be abstinent or be willing to use a medically accepted contraceptive\n             regimen for the duration of the study. Females of child-bearing potential must return\n             a negative urine pregnancy test result prior to vaccination with the vaccine.\n\n        Exclusion Criteria:\n\n          -  Known hypersensitivity to a previous vaccination with influenza vaccine or allergy to\n             eggs, ovalbumin, chicken protein, neomycin, polymyxin, or any components of the\n             vaccine.\n\n          -  Clinical signs of an active infection.\n\n          -  A clinically significant medical condition.\n\n          -  Vaccination with a seasonal or experimental influenza virus vaccine in the 6 months\n             preceding study entry.\n\n          -  Females who are pregnant or lactating."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "59 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 23, 2013", 
        "firstreceived_results_date": "November 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01863433", 
            "org_study_id": "CSLCT-TIV-13-84", 
            "secondary_id": "2013-001420-19"
        }, 
        "intervention": {
            "arm_group_label": "Trivalent Influenza Vaccine", 
            "intervention_name": "Trivalent Influenza Vaccine", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "January 14, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "London", 
                    "country": "United Kingdom", 
                    "zip": "NW10 7EW"
                }, 
                "name": "Study Site"
            }
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase IV, Single-Centre, Open-label Study to Evaluate the Immunogenicity and Safety of the 2013/2014 Formulation of a bioCSL Split Virion, Inactivated Influenza Vaccine in Healthy Volunteers Aged 18-60 Years", 
        "overall_official": {
            "affiliation": "bioCSL PTY LTD", 
            "last_name": "bioCSL Head of Clinical Operations", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "As per the criteria specified in the CPMP/BWP/214/96 Note for Guidance on Harmonisation of Requirements for Influenza Vaccines. For haemagglutination inhibition (HI), seroconversion (H1N1, H3N2, and B influenza virus strains) is defined as achieving a post-vaccination titre of \u2265 40 for those participants with a pre-vaccination HI titre of < 10.  A significant increase (H1N1, H3N2, and B influenza virus strains) is defined as a four-fold or greater increase in HI titre for those participants with a pre-vaccination HI titre of \u2265 10.", 
                "measure": "The Percentage of Evaluable Participants Achieving Seroconversion or Significant Increase in Antibody Titre.", 
                "safety_issue": "No", 
                "time_frame": "Approximately 21 days after vaccination"
            }, 
            {
                "description": "GMFI (H1N1, H3N2, and B influenza virus strains) is defined as the geometric mean of the fold increases of post-vaccination antibody titre over the pre-vaccination antibody titre.", 
                "measure": "The Geometric Mean Fold Increase (GMFI) in Antibody Titre After Vaccination.", 
                "safety_issue": "No", 
                "time_frame": "Approximately 21 days after vaccination"
            }, 
            {
                "description": "For the H1N1, H3N2, and B influenza virus strains. Note: No SRH data were collected.", 
                "measure": "The Percentage of Evaluable Participants Achieving a HI Titre \u2265 40 or Single Radial Haemolysis (SRH) Area \u2265 25 mm2.", 
                "safety_issue": "No", 
                "time_frame": "Approximately 21 days after vaccination"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01863433"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The percentage of participants reporting any solicited AEs.", 
                "measure": "Type and Frequency of Any Solicited Adverse Events (AEs)", 
                "safety_issue": "Yes", 
                "time_frame": "During the 4 days after vaccination (Day 0 plus 3 days)"
            }, 
            {
                "description": "The percentage of participants reporting any unsolicited AEs. Unsolicited AEs included AEs other than those specifically solicited.", 
                "measure": "Type and Frequency of Any Unsolicited AEs", 
                "safety_issue": "Yes", 
                "time_frame": "After vaccination until the end of the study; approximately 21 days."
            }
        ], 
        "source": "bioCSL PTY LTD", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "bioCSL PTY LTD", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}